Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301105 | 0.85 | RXFP1 (0.59) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL8335580 | 0.83 | NPC1 (0.58) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL3991159 | 0.83 | RXFP1 (0.56) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL28055395 | 0.83 | TDP1 (0.57) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL13726555 | 0.82 | NPC1 (0.71) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL13464256 | 0.80 | ALDH1A1 (0.47) | RXFP1NPC1TDP1KDM4EALDH1A1 | |
| SCHEMBL11753942 | 0.80 | ERCC5 (0.53) | MEN1KMT2AKDM4EALDH1A1PARP1 | |
| SCHEMBL7911583 | 0.80 | ALDH1A1 (0.68) | NPC1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL28294170 | 0.79 | RXFP1 (0.53) | RXFP1NPC1MEN1KMT2ATDP1 | |
| SCHEMBL11757716 | 0.79 | ALDH1A1 (0.62) | NPC1MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112347-B1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-9988350-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20170320821-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9718771-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| EP-3112347-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362368-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2016-12-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | RXFP1 493/4885NPC1 2993/4885MEN1 3047/4885 |
| US-20160362368-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | S1PR1, S1PR3, S1PR2 | RXFP1 64/4885NPC1 372/4885MEN1 363/4885 |
| US-20170320821-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | S1PR3, S1PR1, S1PR2 | RXFP1 56/4885NPC1 342/4885MEN1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.